161 related articles for article (PubMed ID: 38367972)
1. Study protocol for FASTRAK: a randomised controlled trial evaluating the cost impact and effectiveness of FAST-MRI for HCC suRveillance in pAtients with high risK of liver cancer.
Nahon P; Ronot M; Sutter O; Natella PA; Baloul S; Durand-Zaleski I; Audureau E
BMJ Open; 2024 Feb; 14(2):e083701. PubMed ID: 38367972
[TBL] [Abstract][Full Text] [Related]
2. Early hepatocellular carcinoma detection using magnetic resonance imaging is cost-effective in high-risk patients with cirrhosis.
Nahon P; Najean M; Layese R; Zarca K; Segar LB; Cagnot C; Ganne-Carrié N; N'Kontchou G; Pol S; Chaffaut C; Carrat F; Ronot M; Audureau E; Durand-Zaleski I; ; ; ;
JHEP Rep; 2022 Jan; 4(1):100390. PubMed ID: 34977518
[TBL] [Abstract][Full Text] [Related]
3. Gadoxetate-enhanced abbreviated MRI is highly accurate for hepatocellular carcinoma screening.
Vietti Violi N; Lewis S; Liao J; Hulkower M; Hernandez-Meza G; Smith K; Babb JS; Chin X; Song J; Said D; Kihira S; Sirlin CB; Reeder SB; Bashir MR; Fowler KJ; Ferket BS; Sigel K; Taouli B
Eur Radiol; 2020 Nov; 30(11):6003-6013. PubMed ID: 32588209
[TBL] [Abstract][Full Text] [Related]
4. Comparison of biannual ultrasonography and annual non-contrast liver magnetic resonance imaging as surveillance tools for hepatocellular carcinoma in patients with liver cirrhosis (MAGNUS-HCC): a study protocol.
Kim HA; Kim KA; Choi JI; Lee JM; Lee CH; Kang TW; Ku YM; Lee SL; Park YS; Yoon JH; Kim SH; Choi MH
BMC Cancer; 2017 Dec; 17(1):877. PubMed ID: 29268722
[TBL] [Abstract][Full Text] [Related]
5. Cost-Utility Analysis of Non-Contrast Abbreviated Magnetic Resonance Imaging for Hepatocellular Carcinoma Surveillance in Cirrhosis.
Decharatanachart P; Pan-Ngum W; Peeraphatdit T; Tanpowpong N; Tangkijvanich P; Treeprasertsuk S; Rerknimitr R; Chaiteerakij R
Gut Liver; 2024 Jan; 18(1):135-146. PubMed ID: 37560799
[TBL] [Abstract][Full Text] [Related]
6. Abbreviated-protocol screening MRI vs. complete-protocol diagnostic MRI for detection of hepatocellular carcinoma in patients with cirrhosis: An equivalence study using LI-RADS v2018.
Khatri G; Pedrosa I; Ananthakrishnan L; de Leon AD; Fetzer DT; Leyendecker J; Singal AG; Xi Y; Yopp A; Yokoo T
J Magn Reson Imaging; 2020 Feb; 51(2):415-425. PubMed ID: 31209978
[TBL] [Abstract][Full Text] [Related]
7. Magnetic Resonance Imaging Is Cost-Effective for Hepatocellular Carcinoma Surveillance in High-Risk Patients With Cirrhosis.
Kim HL; An J; Park JA; Park SH; Lim YS; Lee EK
Hepatology; 2019 Apr; 69(4):1599-1613. PubMed ID: 30365164
[TBL] [Abstract][Full Text] [Related]
8. MRI With Liver-Specific Contrast for Surveillance of Patients With Cirrhosis at High Risk of Hepatocellular Carcinoma.
Kim SY; An J; Lim YS; Han S; Lee JY; Byun JH; Won HJ; Lee SJ; Lee HC; Lee YS
JAMA Oncol; 2017 Apr; 3(4):456-463. PubMed ID: 27657493
[TBL] [Abstract][Full Text] [Related]
9. Comparative efficacy of an optimal exam between ultrasound versus abbreviated MRI for HCC screening in NAFLD cirrhosis: A prospective study.
Huang DQ; Fowler KJ; Liau J; Cunha GM; Louie AL; An JY; Bettencourt R; Jung J; Gitto Z; Hernandez C; Lopez SJ; Gupta H; Sirlin CB; Marks RM; Loomba R
Aliment Pharmacol Ther; 2022 Apr; 55(7):820-827. PubMed ID: 35229334
[TBL] [Abstract][Full Text] [Related]
10. Noncontrast magnetic resonance imaging versus ultrasonography for hepatocellular carcinoma surveillance (MIRACLE-HCC): study protocol for a prospective randomized trial.
An C; Kim DY; Choi JY; Han KH; Roh YH; Kim MJ
BMC Cancer; 2018 Sep; 18(1):915. PubMed ID: 30249190
[TBL] [Abstract][Full Text] [Related]
11. Cost Effectiveness of Hepatocellular Carcinoma Surveillance After a Sustained Virologic Response to Therapy in Patients With Hepatitis C Virus Infection and Advanced Fibrosis.
Farhang Zangneh H; Wong WWL; Sander B; Bell CM; Mumtaz K; Kowgier M; van der Meer AJ; Cleary SP; Janssen HLA; Chan KKW; Feld JJ
Clin Gastroenterol Hepatol; 2019 Aug; 17(9):1840-1849.e16. PubMed ID: 30580095
[TBL] [Abstract][Full Text] [Related]
12. Comparison of non-contrast abbreviated MRI and ultrasound as surveillance modalities for HCC.
Kim DH; Yoon JH; Choi MH; Lee CH; Kang TW; Kim HA; Ku YM; Lee JM; Kim SH; Kim KA; Lee SL; Choi JI
J Hepatol; 2024 Apr; ():. PubMed ID: 38636849
[TBL] [Abstract][Full Text] [Related]
13. Abbreviated MRI for hepatocellular carcinoma screening: A systematic review and meta-analysis.
Gupta P; Soundararajan R; Patel A; Kumar-M P; Sharma V; Kalra N
J Hepatol; 2021 Jul; 75(1):108-119. PubMed ID: 33548385
[TBL] [Abstract][Full Text] [Related]
14. Contrast-enhanced US with Perfluorobutane(Sonazoid) used as a surveillance test for Hepatocellular Carcinoma (HCC) in Cirrhosis (SCAN): an exploratory cross-sectional study for a diagnostic trial.
Park JH; Park MS; Lee SJ; Jeong WK; Lee JY; Park MJ; Han K; Nam CM; Park SH; Lee KH
BMC Cancer; 2017 Apr; 17(1):279. PubMed ID: 28420329
[TBL] [Abstract][Full Text] [Related]
15. Annual contrast-enhanced magnetic resonance imaging is highly effective in the surveillance of hepatocellular carcinoma among cirrhotic patients.
Demirtas CO; Gunduz F; Tuney D; Baltacioglu F; Kani HT; Bugdayci O; Alahdab YO; Ozdogan OC
Eur J Gastroenterol Hepatol; 2020 Apr; 32(4):517-523. PubMed ID: 31524775
[TBL] [Abstract][Full Text] [Related]
16. Current Landscape and Future Perspectives of Abbreviated MRI for Hepatocellular Carcinoma Surveillance.
Park HJ; Seo N; Kim SY
Korean J Radiol; 2022 Jun; 23(6):598-614. PubMed ID: 35434979
[TBL] [Abstract][Full Text] [Related]
17. Surveillance and treatment of primary hepatocellular carcinoma (aka. STOP HCC): protocol for a prospective cohort study of high-risk patients for HCC using GALAD-score.
Truong TN; Pham TND; Hoang LB; Nguyen VT; Dao HV; Dao DVB; Alessy S; Pham HB; Pham TTT; Nguyen LDD; Nguyen K; Abaalkhail F; Manal M; Mawardi M; AlZahrani M; Alswat K; Alghamdi H; Sanai FM; Siddiqui MA; Nguyen NH; Vaidya D; Phan HT; Johnson PJ; Alqahtani SA; Dao DY
BMC Cancer; 2023 Sep; 23(1):875. PubMed ID: 37723439
[TBL] [Abstract][Full Text] [Related]
18. Abbreviated MRI for Secondary Surveillance of Recurrent Hepatocellular Carcinoma After Presumed Curative Treatment.
Jeon SK; Lee DH; Hur BY; Park SJ; Kim SW; Park J; Suh KS; Lee KW; Yi NJ; Han JK
J Magn Reson Imaging; 2023 Nov; 58(5):1375-1383. PubMed ID: 36825827
[TBL] [Abstract][Full Text] [Related]
19. Hepatocellular carcinoma detection: diagnostic performance of a simulated abbreviated MRI protocol combining diffusion-weighted and T1-weighted imaging at the delayed phase post gadoxetic acid.
Besa C; Lewis S; Pandharipande PV; Chhatwal J; Kamath A; Cooper N; Knight-Greenfield A; Babb JS; Boffetta P; Padron N; Sirlin CB; Taouli B
Abdom Radiol (NY); 2017 Jan; 42(1):179-190. PubMed ID: 27448609
[TBL] [Abstract][Full Text] [Related]
20. Surveillance programme of cirrhotic patients for early diagnosis and treatment of hepatocellular carcinoma: a cost effectiveness analysis.
Bolondi L; Sofia S; Siringo S; Gaiani S; Casali A; Zironi G; Piscaglia F; Gramantieri L; Zanetti M; Sherman M
Gut; 2001 Feb; 48(2):251-9. PubMed ID: 11156649
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
